

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/08, C07K 7/14, C12N 5/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/45945</b> <b>(43) International Publication Date:</b> 16 September 1999 (16.09.99)																		
<b>(21) International Application Number:</b> PCT/US99/05194 <b>(22) International Filing Date:</b> 8 March 1999 (08.03.99)  <b>(30) Priority Data:</b> <table border="0"><tr><td>60/077,382</td><td>10 March 1998 (10.03.98)</td><td>US</td></tr><tr><td>60/081,262</td><td>9 April 1998 (09.04.98)</td><td>US</td></tr><tr><td>60/083,670</td><td>30 April 1998 (30.04.98)</td><td>US</td></tr><tr><td>60/090,096</td><td>19 June 1998 (19.06.98)</td><td>US</td></tr><tr><td>60/090,216</td><td>22 June 1998 (22.06.98)</td><td>US</td></tr><tr><td>60/099,957</td><td>11 September 1998 (11.09.98)</td><td>US</td></tr></table> <b>(71) Applicant:</b> UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; Suite 313, 3716 South Hope Street, Los Angeles, CA 90007-4344 (US);  <b>(71)(72) Applicants and Inventors:</b> RODGERS, Kathleen, E. [US/US]; 4403 Galeano Street, Long Beach, CA 90815 (US). DIZEREGA, Gere [US/US]; 1270 Hillcrest Avenue, Pasadena, CA 91106 (US).  <b>(74) Agent:</b> HARPER, David, S.; McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago, IL 60606 (US).		60/077,382	10 March 1998 (10.03.98)	US	60/081,262	9 April 1998 (09.04.98)	US	60/083,670	30 April 1998 (30.04.98)	US	60/090,096	19 June 1998 (19.06.98)	US	60/090,216	22 June 1998 (22.06.98)	US	60/099,957	11 September 1998 (11.09.98)	US	<b>(81) Designated States:</b> AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
60/077,382	10 March 1998 (10.03.98)	US																		
60/081,262	9 April 1998 (09.04.98)	US																		
60/083,670	30 April 1998 (30.04.98)	US																		
60/090,096	19 June 1998 (19.06.98)	US																		
60/090,216	22 June 1998 (22.06.98)	US																		
60/099,957	11 September 1998 (11.09.98)	US																		
<b>(54) Title:</b> IMPROVED RADIATION THERAPY METHODS  <b>(57) Abstract</b> <p>The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor agonists.</p>																				

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## IMPROVED RADIATION THERAPY METHODS

### Cross Reference

5           This application is a Continuation-In-Part of U.S. Provisional Application  
Nos. 60/077,382 filed March 10, 1998; 60/083670 filed April 29, 1998; 60/081,262  
filed April 9, 1998; 60/090216 filed June 22, 1998; 60/090,096 filed June 19, 1998;  
and 60/099,957 filed Sept. 11, 1998.

### 10    Background of the Invention

          Radiation therapy is currently one of the most useful methods of treating  
cancerous tumors. However, radiation therapy damages normal tissue surrounding the  
tumor (U.S. Patent No. 5,599,712, incorporated by reference herein in its entirety).  
This damage can include fibrosis, remodeling of the extracellular matrix, vascular  
15   damage, aberrant angiogenesis, pneumonitis, atherogenesis, osteonecrosis, mucositis,  
immunosuppression and functional impairment (U.S. Patent No. 5,616,561,  
incorporated by reference herein in its entirety). As a result of these radiation-induced  
side effects, techniques have been developed to minimize radiation-induced damage  
to surrounding normal tissues by limiting radiation to the lowest level effective for  
20   cancer treatment. Since there is a direct relationship between the amount of radiation  
and the effectiveness of the treatment, this method compromises the overall  
effectiveness of the treatment.

          For some cancer patients, hematopoietic toxicity frequently limits the  
opportunity for radiation dose escalation (Watanabe et al., *British J. Haematol.*  
25   94:619-627 (1996)). Repeated or high dose cycles of radiation therapy may be

responsible for severe stem cell depletion leading to important long-term hematopoietic sequelae and marrow exhaustion (Masse et al., *Blood* 91:441-449 (1998). Such stem cell depletion leads to depletion of the full range of hematopoietic lineage specific cells, including megakaryocytes, platelets, monocytes, neutrophils, and lymphocytes, and the resulting complications of such depletion. For example, in patients suffering from depressed levels of platelets (thrombocytopenia) the inability to form clots is the most immediate and serious consequence, a potentially fatal complication of many therapies for cancer. Such cancer patients are generally treated for this problem with platelet transfusions. Other patients frequently requiring platelet transfusions are those undergoing bone marrow transplantation or patients with aplastic anemia. Platelets for such procedures are obtained by plateletpheresis from normal donors. Like most human blood products, platelets for transfusion have a relatively short shelf-life and also expose the patients to considerable risk of exposure to dangerous viruses, such as the human immunodeficiency virus (HIV).

The administration of hematopoietic growth factors may reduce short-term side effects induced by radiation, but has been hypothesized to cause long-term hematopoietic damage (Masse et al., 1998; Watanabe et al., 1996). Several studies have suggested that co-administration of negative hematopoietic regulators can minimize radiation therapy-induced myelotoxicity by reducing the number of progenitor cells that enter the cell cycle. (Watanabe et al., 1996; Dunlop et al., *Blood* 79:2221-2225 (1992); Paukovits et al., *Blood* 81:1755-1761; Bogden et al., *Annals N.Y. Acad. Sci.* 628:126-139 (1991); Deeg et al., *Ann. Hematol.* 74:117-122 (1997); Masse et al., 1998). This treatment is based on the premise that hematopoietic stem

cells are relatively protected from radiation-related toxicity when quiescent, particularly when the malignant cells are proliferating (Deeg et al., (1997)).

Bone marrow contains pluripotent stem cells that are capable of reconstituting the entire hematopoietic system. Bone marrow transplantation has been used to treat various intractable hematopoietic diseases including leukemia and severe aplastic anemia. (U.S. Patent No. 5,186,931, incorporated by reference herein in its entirety.) Typically, a bone marrow transplant patient is subjected to irradiation to reduce the leukocyte count to zero, followed by transplantation of bone marrow cells which function by producing a sufficient number of normal leukocytes. However, various complications, such as death, infectious diseases, graft versus host disease, radiation nephritis, and interstitial pneumonia frequently occur during the time period between transplantation and the return to normal white blood cell levels after transplantation.

As a result of these frequent side effects, no satisfactory methods are currently available for supporting bone marrow transplantation which are capable of both increasing survival of bone marrow transplant patients and also accelerating the reconstitution of the hematopoietic system of the patient.

Chronic radiation injuries, such as radiation nephropathy, have been viewed as inevitable, progressive and untreatable (Moulder et al., *Bone Marrow Transplantation* 19:729-735 (1997)). The progressive and untreatable nature of late tissue damage follows from the assumption that the injury is due to delayed mitotic cell death resulting from genetic injury that is produced and irrevocably fixed in place at the time of irradiation (Moulder et al., 1997). Under this view, the only way to decrease the probability of injury is by limiting the radiation dose or shielding the at risk organs.

However, recent results indicate that late-onset radiation-induced tissue injury involves complex and dynamic interactions among parenchymal and vascular cells within a particular organ (Moulder et al., 1997). This model of chronic radiation injury suggests that pharmacological intervention after radiation exposure would be effective.

Thus, despite advances in the field of radiation therapy, prior art methods have proven to be of limited utility in minimizing radiation-induced tissue damage, and improving the efficacy of tumor radiation therapy and bone marrow transplantation. Thus, there is a need for improved therapeutic methods to mitigate radiation induced tissue damage and to improve the effectiveness of radiation therapy. Furthermore, the ability to stimulate endogenous platelet formation in thrombocytopenic patients with a concomitant reduction in their dependence on platelet transfusion would be of great benefit. In addition the ability to correct or prevent thrombocytopenia in patients undergoing radiation therapy or chemotherapy for cancer would make such treatments safer and possibly permit increases in the intensity of the therapy thereby yielding greater anti-cancer effects.

### **Summary of the Invention**

In one aspect, the present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues

thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor agonists to a patient in need thereof.

In another aspect of the present invention, an improved cell culture medium and kits are provided for the production of megakaryocytes and platelets wherein the improvement comprises addition to the cell culture medium of an effective amount of  
5 angiotensinogen, AI, AI analogues, AI fragments and analogues thereof, AII, AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor agonists.

These aspects and other aspects of the invention become apparent in light of the following detailed description.

10

#### **Brief Description of the Drawings**

**Figure 1** is a graph showing the effect of AII treatment two days prior to exposure on post-irradiation mouse mortality.

15 **Figure 2** is a graph showing the effect of AII treatment on the day of exposure on post-irradiation mouse mortality.

**Figure 3** is a graph showing the effect of AII treatment two days following exposure on post-irradiation mouse mortality.

**Figure 4** is a graph showing the effect of AII treatment two days prior to exposure on  
20 white blood cell number after irradiation.

**Figure 5** is a graph showing the effect of AII treatment on the day of exposure on white blood cell number after irradiation.

**Figure 6** is a graph showing the effect of AII treatment two days following exposure on white blood cell number after irradiation.

**Figure 7** is a graph showing the effect of AII treatment two days prior to exposure on megakaryocyte number after irradiation.

**Figure 8** is a graph showing the effect of AII treatment on the day of exposure on megakaryocyte number after irradiation.

5 **Figure 9** is a graph showing the effect of AII treatment two days following exposure on megakaryocyte percentage after irradiation.

**Figure 10** is a graph showing the effect of AII treatment two days prior to exposure on monocyte number after irradiation.

10 **Figure 11** is a graph showing the effect of AII treatment on the day of exposure on monocyte number after irradiation.

**Figure 12** is a graph showing the effect of AII treatment two days following exposure on monocyte number after irradiation.

**Figure 13** is a graph showing the effect of AII treatment two days prior to exposure on neutrophil number after irradiation.

15 **Figure 14** is a graph showing the effect of AII treatment on the day of exposure on neutrophil number after irradiation.

**Figure 15** is a graph showing the effect of AII treatment two days following exposure on neutrophil number after irradiation.

20 **Figure 16** is a graph showing the effect of AII treatment two days prior to exposure on lymphocyte number after irradiation.

**Figure 17** is a graph showing the effect of AII treatment on the day of exposure on lymphocyte number after irradiation.

**Figure 18** is a graph showing the effect of AII treatment two days following exposure on lymphocyte number after irradiation.



**Figure 19** is a graph showing is a graph showing the effect of AII analogues and fragments treatment on white blood cell number after irradiation.

**Figure 20** is a graph showing is a graph showing the effect of AII analogues and fragments treatment on platelet number after irradiation.

5 **Figure 21** is a graph showing the effect of AII on mouse survival receiving bone marrow transplantation after lethal irradiation.

**Figure 22** is a graph showing the effect of AII analogues and fragments treatment on white blood cell number after irradiation.

**Figure 23** is a graph showing the effect of AII on white blood cell number in the  
10 blood of mice receiving bone marrow transplantation after lethal irradiation.

**Figure 24** is a graph showing the effect of AII on white blood cell number in the blood of mice receiving bone marrow transplantation after lethal irradiation..

#### **Detailed Description of the Preferred Embodiments**

15 All references patents and patent applications are hereby incorporated by reference in their entirety.

The present invention fulfills the needs for improved therapeutic methods to mitigate radiation induced tissue damage, to improve the effectiveness of radiation therapy, to support bone marrow transplantation, and to promote megakaryocyte  
20 production and mobilization and platelet production.

As defined herein the phrase "mitigation of tissue damage" refers not only to reduction of damage, but also encompasses recovery of tissue from damage. As used herein "tissue" refers to any tissue type, and also includes hematopoietic stem and progenitor cells, white blood cells and platelets.

As defined herein the term "megakaryocyte mobilization" refers to the movement of a megakaryocyte precursor cell from the bone marrow into the periphery.

As defined herein, the phrase "improved platelet production" or "improved  
5 megakaryocyte production," means that the number of platelets or megakaryocytes is significantly elevated above the normal range of platelets or megakaryocytes in the particular mammal involved. The elevation of platelet or megakaryocyte counts may occur in a time-dependent manner, and may be cyclical, increasing and then constant or decreasing, or constant, etc.

10 Unless otherwise indicated, the term "active agents" as used herein refers to the group of compounds comprising angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof and AII AT<sub>2</sub> type 2 receptor agonists.

Within this application, unless otherwise stated, the techniques utilized may be  
15 found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991, Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutscher, ed., (1990) Academic Press, Inc.); *PCR*  
20 *Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2<sup>nd</sup> Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, NJ), and the Ambion 1998 Catalog (Ambion, Austin, TX).

U.S. Patent No. 5,015,629 to DiZerega (the entire disclosure of which is hereby incorporated by reference) describes a method for increasing the rate of healing of wound tissue, comprising the application to such tissue of angiotensin II (AII) in an amount which is sufficient for said increase. The application of AII to wound tissue significantly increases the rate of wound healing, leading to a more rapid re-epithelialization and tissue repair. The term AII refers to an octapeptide present in humans and other species having the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:1]. The biological formation of angiotensin is initiated by the action of renin on the plasma substrate angiotensinogen. The substance so formed is a decapeptide called angiotensin I (AI) which is converted to AII by the converting enzyme angiotensinase which removes the C-terminal His-Leu residues from AI (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu [SEQ ID NO:37]). AII is a known pressor agent and is commercially available. The use of AII analogues and fragments, AT2 agonists, as well as AIII and AIII analogues and fragments in wound healing has also been described. (U.S. Patent No. 5,629,292; U.S. Patent No. 5,716,935; WO 96/39164; all references herein incorporated by reference in their entirety.)

Studies have shown that AII increases mitogenesis and chemotaxis in cultured cells that are involved in wound repair, and also increases their release of growth factors and extracellular matrices (diZerega, U.S. Patent No. 5,015,629; Dzau et. al., *J. Mol. Cell. Cardiol.* 21:S7 (Supp III) 1989; Berk et. al., *Hypertension* 13:305-14 (1989); Kawahara, et al., *BBRC* 150:52-9 (1988); Naftilan, et al., *J. Clin. Invest.* 83:1419-23 (1989); Taubman et al., *J. Biol. Chem* 264:526-530 (1989); Nakahara, et al., *BBRC* 184:811-8 (1992); Stouffer and Owens, *Circ. Res.* 70:820 (1992); Wolf, et al., *Am. J. Pathol.* 140:95-107 (1992); Bell and Madri, *Am. J. Pathol.* 137:7-12

(1990). In addition, AII was shown to be angiogenic in rabbit corneal eye and chick chorioallantoic membrane models (Fernandez, et al., *J. Lab. Clin. Med.* 105:141 (1985); LeNoble, et al., *Eur. J. Pharmacol.* 195:305-6 (1991). Therefore, AII may accelerate wound repair through increased neovascularization, growth factor release, reepithelialization and/or production of extracellular matrix.

AII has also been implicated in both cell growth and differentiation (Meffert et al., *Mol. and Cellul. Endocrin.* 122:59 (1996)). Two main classes of AII receptors, AT<sub>1</sub> and AT<sub>2</sub> have been identified (Meffert, 1996). The growth-promoting effects of AII have been attributed to mediation by the AT<sub>1</sub> receptor, while some evidence suggests that the AT<sub>2</sub> receptor may be involved in mediation of the cell differentiation effects of AII (Bedecs et al., *Biochem. J.* 325:449 (1997)).

The effects of AII receptor and AII receptor antagonists have been examined in two experimental models of vascular injury and repair which suggest that both AII receptor subtypes (AT<sub>1</sub> and AT<sub>2</sub>) play a role in wound healing (Janiak et al., *Hypertension* 20:737-45 (1992); Prescott, et al., *Am. J. Pathol.* 139:1291-1296 (1991); Kauffman, et al., *Life Sci.* 49:223-228 (1991); Viswanathan, et al., *Peptides* 13:783-786 (1992); Kimura, et al., *BBRC* 187:1083-1090 (1992).

Many studies have focused upon AII(1-7) (AII residues 1-7) or other fragments of AII to evaluate their activity. AII(1-7) elicits some, but not the full range of effects elicited by AII. Pfeilschifter, et al., *Eur. J. Pharmacol.* 225:57-62 (1992); Jaiswal, et al., *Hypertension* 19(Supp. II):II-49-II-55 (1992); Edwards and Stack, *J. Pharmacol. Exper. Ther.* 266:506-510 (1993); Jaiswal, et al., *J. Pharmacol. Exper. Ther.* 265:664-673 (1991); Jaiswal, et al., *Hypertension* 17:1115-1120 (1991); Portsi, et al., *Br. J. Pharmacol.* 111:652-654 (1994).

While a single pilot study has suggested that AII-induced hypertension might be effective in combination with radiation therapy in the treatment of lung cancer patients (Kato et al., *Radiation Medicine* 11:86-90 (1993)), many studies have demonstrated that antagonists of angiotensin converting enzyme (ACE), which mediate the production of AII, are effective in reducing radiation nephropathy, bone marrow transplantation nephropathy, and acute radiation injury (Moulder et al., *Int. J. Radiation Onc. Biol. Phys.* 27:93-99 (1993); Moulder et al., *Bone Marrow Transpl.* 19:729-735 (1997); Moulder et al., *Radiation Res.* 146:106-110 (1996); Cohen et al., *J. Lab. Clin. Med.* 129:536-547 (1997); Moulder et al., *Radiation Res.* 136:404-407 (1993); Yoon et al., *Int. J. Radiat. Oncol. Biol. Phys.* 30:873-878 (1994); Ward et al., *Radiation Res.* 135:81-87 (1993); Cohen et al., *Lab. Invest.* 75:349-360 (1996); Cohen et al., *J. Lab. Clin. Med.* 124:371-380 (1994); Gerarci et al., *Radiation Res.* 143:58-68 (1995)). The effect of the ACE inhibitors has been demonstrated, in at least one case, to be directly caused by the reduction of activation of the AT<sub>1</sub> receptor by AII (Moulder et al., *Radiation Res.* 146:106-110 (1996)). These results have led to the suggestion that, in the case of radiation nephropathy, the most effective treatment is the use of ACE inhibitors (Moulder et al., *Bone Marrow Transplantation* 19:729-735 (1997)).

Furthermore, it has recently been demonstrated that angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, AII, AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor agonists are potent stimulators of hematopoietic stem cell proliferation (U.S. Patent Application, Serial No. 09/012,400, hereby incorporated by reference in its entirety). Therefore, it would be expected that the use of these compounds might cause long-term

hematopoietic damage if used in conjunction with radiation therapy (Masse et al., 1998; Watanabe et al., 1996).

Based on all of the above, it would be unexpected that the use of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, AII, AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2  
5 receptor agonists would be effective in reducing radiation-induced human tissue damage or in treating patients in need of radiation therapy.

None of these studies teach or suggest the use of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII  
10 analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor agonists to stimulate the production and mobilization of megakaryocytes, or to stimulate the production of platelets.

A peptide agonist selective for the AT<sub>2</sub> receptor (AII has 100 times higher affinity for AT<sub>2</sub> than AT<sub>1</sub>) is p-aminophenylalanine<sup>6</sup>-AII ["(p-NH<sub>2</sub>-Phe)<sup>6</sup>-AII"],  
15 Asp-Arg-Val-Tyr-Ile-Xaa-Pro-Phe [SEQ ID NO.36] wherein Xaa is p-NH<sub>2</sub>-Phe (Speth and Kim, *BBRC* 169:997-1006 (1990). This peptide gave binding characteristics comparable to AT<sub>2</sub> antagonists in the experimental models tested (Catalioto, et al., *Eur. J. Pharmacol.* 256:93-97 (1994); Bryson, et al., *Eur. J. Pharmacol.* 225:119-127 (1992).

20 The active AI, AI analogues, AI fragments and analogues thereof, AII analogues, fragments of AII and analogues thereof of particular interest in accordance with the present invention are characterized as comprising a sequence consisting of at least three contiguous amino acids of groups R<sup>1</sup>-R<sup>8</sup> in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group,

5  $R^A$  is suitably selected from Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic acid), Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc,

$R^B$  is suitably selected from Arg, Lys, Ala, Orn, Ser(Ac); Sar, D-Arg and D-Lys;

10  $R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

15  $R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group.

20 Compounds falling within the category of AT2 agonists useful in the practice of the invention include the AII analogues set forth above subject to the restriction that  $R^6$  is p-NH<sub>2</sub>-Phe. In addition to peptide agents, various nonpeptidic agents (e.g., peptidomimetics) having the requisite AT2 agonist activity are further contemplated for use in accordance with the present invention.

Particularly preferred combinations for R<sup>A</sup> and R<sup>B</sup> are Asp-Arg, Asp-Lys, Glu-Arg and Glu-Lys. Particularly preferred embodiments of this class include the following: AII, AIII or AII(2-8), Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]; AII(3-8), also known as des1-AIII or AIV, Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:3];  
5 AII(1-7), Asp-Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:4]; AII(2-7), Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:5]; AII(3-7), Val-Tyr-Ile-His-Pro [SEQ ID NO:6]; AII(5-8), Ile-His-Pro-Phe [SEQ ID NO:7]; AII(1-6), Asp-Arg-Val-Tyr-Ile-His [SEQ ID NO:8]; AII(1-5), Asp-Arg-Val-Tyr-Ile [SEQ ID NO:9]; AII(1-4), Asp-Arg-Val-Tyr [SEQ ID NO:10]; and AII(1-3), Asp-Arg-Val [SEQ ID NO:11]. Other preferred embodiments  
10 include: Arg-norLeu-Tyr-Ile-His-Pro-Phe [SEQ ID NO:12] and Arg-Val-Tyr-norLeu-His-Pro-Phe [SEQ ID NO:13]. Still another preferred embodiment encompassed within the scope of the invention is a peptide having the sequence Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe [SEQ ID NO:31]. AII(6-8), His-Pro-Phe [SEQ ID NO:14] and AII(4-8), Tyr-Ile-His-Pro-Phe [SEQ ID NO:15] were also tested and found not to be  
15 effective.

A class of particularly preferred compounds in accordance with the present invention consists of those with the following general structure:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

20 R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;


R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent.



Particularly preferred embodiment of this class are selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38

Another class of compounds of particular interest in accordance with the  
5 present invention are those of the general formula II



in which  $R^2$  is selected from the group consisting of H, Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile,  
10 Gly, Pro, Aib, Acpc and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val  
and Gly;

15  $R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr.

A particularly preferred subclass of the compounds of general formula II has  
the formula

20  $R^2-R^3$ -Tyr- $R^5$ -His-Pro-Phe [SEQ ID NO:16]

wherein  $R^2$ ,  $R^3$  and  $R^5$  are as previously defined. Particularly preferred is angiotensin III of the formula Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]. Other

preferred compounds include peptides having the structures Arg-Val-Tyr-Gly-His-Pro-Phe [SEQ ID NO:17] and Arg-Val-Tyr-Ala-His-Pro-Phe [SEQ ID NO:18]. The fragment AII(4-8) was ineffective in repeated tests; this is believed to be due to the exposed tyrosine on the N-terminus.

- 5 In the above formulas, the standard three-letter abbreviations for amino acid residues are employed. In the absence of an indication to the contrary, the L-form of the amino acid is intended. Other residues are abbreviated as follows:

TABLE 1

## 10 Abbreviation for Amino Acids

Me <sup>2</sup> Gly	N,N-dimethylglycyl
Bet	1-carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt (betaine)
Suc	Succinyl
Phe(Br)	p-bromo-L-phenylalanyl
azaTyr	aza- $\alpha'$ -homo-L-tyrosyl
Acpc	1-aminocyclopentane carboxylic acid
Aib	2-aminoisobutyric acid
Sar	N-methylglycyl (sarcosine)

- It has been suggested that AII and its analogues adopt either a *gamma* or a *beta* turn (Regoli, et al., *Pharmacological Reviews* 26:69 (1974). In general, it is believed that neutral side chains in position R<sup>3</sup>, R<sup>5</sup> and R<sup>7</sup> may be involved in maintaining the appropriate distance between active groups in positions R<sup>4</sup>, R<sup>6</sup> and R<sup>8</sup> primarily responsible for binding to receptors and/or intrinsic activity. Hydrophobic
- 15

side chains in positions  $R^3$ ,  $R^5$  and  $R^8$  may also play an important role in the whole conformation of the peptide and/or contribute to the formation of a hypothetical hydrophobic pocket.

Appropriate side chains on the amino acid in position  $R^2$  may contribute to  
5 affinity of the compounds for target receptors and/or play an important role in the conformation of the peptide. For this reason, Arg and Lys are particularly preferred as  $R^2$ .

For purposes of the present invention, it is believed that  $R^3$  may be involved in the formation of linear or nonlinear hydrogen bonds with  $R^5$  (in the gamma turn  
10 model) or  $R^6$  (in the beta turn model).  $R^3$  would also participate in the first turn in a beta antiparallel structure (which has also been proposed as a possible structure). In contrast to other positions in general formula I, it appears that beta and gamma branching are equally effective in this position. Moreover, a single hydrogen bond may be sufficient to maintain a relatively stable conformation. Accordingly,  $R^3$  may  
15 suitably be selected from Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr. In another preferred embodiment,  $R^3$  is Lys.

With respect to  $R^4$ , conformational analyses have suggested that the side chain in this position (as well as in  $R^3$  and  $R^5$ ) contribute to a hydrophobic cluster believed to be essential for occupation and stimulation of receptors. Thus,  $R^4$  is preferably  
20 selected from Tyr, Thr, Tyr  $(PO_3)_2$ , homoSer, Ser and azaTyr. In this position, Tyr is particularly preferred as it may form a hydrogen bond with the receptor site capable of accepting a hydrogen from the phenolic hydroxyl (Regoli, et al. (1974), *supra*). In a further preferred embodiment,  $R^4$  is Ala.

In position R<sup>5</sup>, an amino acid with a  $\beta$  aliphatic or alicyclic chain is particularly desirable. Therefore, while Gly is suitable in position R<sup>5</sup>, it is preferred that the amino acid in this position be selected from Ile, Ala, Leu, norLeu, Gly and Val.

5 In the AI, AI analogues, AI fragments and analogues thereof, AII, AII analogues, fragments and analogues of fragments of particular interest in accordance with the present invention, R<sup>6</sup> is His, Arg or 6-NH<sub>2</sub>-Phe. The unique properties of the imidazole ring of histidine (e.g., ionization at physiological pH, ability to act as proton donor or acceptor, aromatic character) are believed to contribute to its  
10 particular utility as R<sup>6</sup>. For example, conformational models suggest that His may participate in hydrogen bond formation (in the *beta* model) or in the second turn of the antiparallel structure by influencing the orientation of R<sup>7</sup>. Similarly, it is presently considered that R<sup>7</sup> should be Pro in order to provide the most desirable orientation of R<sup>8</sup>. In position R<sup>8</sup>, both a hydrophobic ring and an anionic carboxyl terminal appear  
15 to be particularly useful in binding of the analogues of interest to receptors; therefore, Tyr and especially Phe are preferred for purposes of the present invention.

Analogues of particular interest include the following:

**TABLE 2**

**Angiotensin II Analogues**

AII Analogue Name	Amino Acid Sequence	Sequence Identifier
Analogue 1	Asp-Arg-Val-Tyr-Val-His-Pro-Phe	SEQ ID NO: 19
Analogue 2	Asn-Arg-Val-Tyr-Val-His-Pro-Phe	SEQ ID NO: 20
Analogue 3	Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe	SEQ ID NO: 21
Analogue 4	Glu-Arg-Val-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 22
Analogue 5	Asp-Lys-Val-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 23

Analogue 6	Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 24
Analogue 7	Asp-Arg-Val-Thr-Ile-His-Pro-Phe	SEQ ID NO: 25
Analogue 8	Asp-Arg-Val-Tyr-Leu-His-Pro-Phe	SEQ ID NO: 26
Analogue 9	Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe	SEQ ID NO: 27
Analogue 10	Asp-Arg-Val-Tyr-Ile-His-Ala-Phe	SEQ ID NO: 28
Analogue 11	Asp-Arg-Val-Tyr-Ile-His-Pro-Tyr	SEQ ID NO: 29
Analogue 12	Pro-Arg-Val-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 30
Analogue 13	Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 31
Analogue 14	Asp-Arg-Val-Tyr(PO <sub>3</sub> ) <sub>2</sub> -Ile-His-Pro-Phe	SEQ ID NO: 32
Analogue 15	Asp-Arg-norLeu-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 33
Analogue 16	Asp-Arg-Val-Tyr-norLeu-His-Pro-Phe	SEQ ID NO: 34
Analogue 17	Asp-Arg-Val-homoSer-Tyr-Ile-His-Pro-Phe	SEQ ID NO: 35

The polypeptides of the instant invention may be synthesized by methods such as those set forth in J. M. Stewart and J. D. Young, *Solid Phase Peptide Synthesis*, 2nd ed., Pierce Chemical Co., Rockford, Ill. (1984) and J. Meienhofer, *Hormonal Proteins and Peptides*, Vol. 2, Academic Press, New York, (1973) for solid phase synthesis and E. Schroder and K. Lubke, *The Peptides*, Vol. 1, Academic Press, New York, (1965) for solution synthesis. The disclosures of the foregoing treatises are incorporated by reference herein.

In general, these methods involve the sequential addition of protected amino acids to a growing peptide chain (U.S. Patent No. 5,693,616, herein incorporated by reference in its entirety). Normally, either the amino or carboxyl group of the first amino acid and any reactive side chain group are protected. This protected amino acid is then either attached to an inert solid support, or utilized in solution, and the next amino acid in the sequence, also suitably protected, is added under conditions amenable to formation of the amide linkage. After all the desired amino acids have been linked in the proper sequence, protecting groups and any solid support are removed to afford the crude polypeptide. The polypeptide is desalted and purified, preferably chromatographically, to yield the final product.

In one aspect, the present invention provides methods and kits for the mitigation of tissue damage due to radiation exposure comprising the administration of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII  
5 AT<sub>2</sub> type 2 receptor agonists (the "active agents").

In another aspect, the present invention provides improved methods and kits for treating a patient afflicted with a neoplastic disease state that is being treated with ionizing or nonionizing radiation, the improvement comprising conjunctive therapy whereby an effective radioprotective amount of the active agents is provided.

10 In another aspect, the present invention provides improved methods and kits for treating a patient in need of radiation therapy, the improvement comprising the administration of the active agents in conjunction with the radiation therapy.

The invention is appropriate for use with any type of ionizing radiation exposure such as therapeutic or accidental X-ray, gamma ray, or beta particle  
15 exposure. Examples of ionizing radiation exposure suitable for treatment with the methods and kits of the present invention include, but are not limited to, clinical radiation therapy, medical diagnostics using radioactive tracers, exposure to naturally occurring ionizing radiation sources such as uranium and radon, wartime exposure, and accidental exposures including occupational exposure at nuclear power facilities,  
20 and medical and research institutions. Examples of nonionizing radiation exposure suitable for treatment with the methods and kits of the present invention include, but are not limited to, ultraviolet light, X-rays, microwaves, radio-frequency waves, and electromagnetic radiation.

Virtually any tissue susceptible to radiation-induced tissue damage can gain protection by use of the active agents of the invention. For example, breast tissue is an excellent candidate for receiving the benefit of the subject invention. Radiation-induced tissue damage can be a fatal side effect of over-exposure to radiation therapy.

5 Typically, the fibrotic reaction common in normal breast tissue surrounding the cancerous tumor being treated with radiation therapy undermines the cosmetic advantages of radiation therapy over surgical treatment. This disadvantage will lead many patients to elect a less effective or more dangerous treatment after radiation therapy.

10 The present invention is also particularly suitable for those patients in need of repeated or high doses of radiation therapy. For some cancer patients, hematopoietic toxicity frequently limits the opportunity for radiation dose escalation (Watanabe et al., *British J. Haematol.* 94:619-627 (1996)). Repeated or high dose cycles of radiation therapy may be responsible for severe stem cell depletion leading to  
15 important long-term hematopoietic sequelae and marrow exhaustion. The methods of the present invention provide for improved mortality and blood cell count when used in conjunction with radiation therapy.

Skin exposure is particularly common in accidental radiation exposure. It is an excellent candidate for the inventive therapy, especially as the compounds of the  
20 invention can be administered topically. Other tissues that are susceptible to radiation-induced damage following accidental or therapeutic ionizing or nonionizing radiation exposure include, but are not limited to: liver, lung, gastrointestinal tract, kidneys, testes, salivary gland, mucosa and brain.

In another aspect, the present invention provides improved methods and kits for supporting bone marrow transplantation comprising the administration of the active agents to a patient in need thereof. These compounds may be administered in combination with auxiliary agents including, but not limited to interleukin (IL)-3, IL-1, IL-4, IL-5, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), anticancer agents, antiviral agents, and antibiotics.

In a further aspect, the present invention provides kits for mitigating radiation induced tissue damage and improving the efficacy of radiation therapy, wherein the kits comprise an effective amount of the active agents of the invention for mitigating radiation induced tissue damage or improving the efficacy of radiation therapy, and instructions for using the amount effective of active agent as a therapeutic. In a preferred embodiment, the kit further comprises a pharmaceutically acceptable carrier, such as those adjuvants described above. In another preferred embodiment, the kit further comprises a means for delivery of the active agent to a patient. Such devices include, but are not limited to syringes, matrical or micellar solutions, bandages, wound dressings, aerosol sprays, lipid foams, transdermal patches, topical administrative agents, polyethylene glycol polymers, carboxymethyl cellulose preparations, crystalloid preparations (e.g., saline, Ringer's lactate solution, phosphate-buffered saline, etc.), viscoelastics, polyethylene glycols, and polypropylene glycols. The means for delivery may either contain the effective amount of angiotensinogen, AI, AI analogues, AI fragments and analogues thereof, AII, AII analogues, AII fragments or analogues thereof or AII AT<sub>2</sub> type 2 receptor



agonists, or may be separate from the compounds, which are then applied to the means for delivery at the time of use.

The methods and kits of the present invention, by mitigating radiation induced tissue damage and improving the efficacy of radiation therapy and bone marrow  
5 transplantation, significantly enhance the utility of presently available treatments both for radiation-induced tissue damage and for clinical radiation therapy.

In a further aspect of the present invention, a method of increasing megakaryocyte production and mobilization and platelet production by exposure to the active agents of the inventions is disclosed. In one embodiment, megakaryocytes  
10 are isolated from bone marrow as described in U.S. Patent No. 5,178,856, incorporated by reference herein in its entirety. Briefly, marrow is flushed from a subject's femur with Iscove's modification of Dulbecco's medium (IMDM) supplemented with Nutridoma-SP (Boehringer Mannheim, Indianapolis, Ind.), a serum-free medium supplement. For culture studies, a single cell suspension is made  
15 by repetitive expulsion through progressively smaller needles. For flow cytometry controls, a monocellular suspension is made by gentle filtration through a 100 micron nylon mesh. Preferably, adherent cells are removed to enrich the numbers of megakaryocytes or their progenitor cells. Up to  $2 \times 10^6$  cells/ml are placed in growth medium at 37° C in a humidified atmosphere in the presence of, preferably, between  
20 about 0.1 ng/ml and about 10 mg/ml of the active agents. The cells are expanded for a period of between 2 and 21 days and cellular proliferation is assessed at various time points during this time period. Subsequent medium changes are performed as needed. In a preferred embodiment, megakaryocyte production and mobilization and platelet production are assessed by the extent of megakaryocyte ploidization by flow

cytometry as described in U.S. Patent No. 5,155,211, incorporated by reference herein in its entirety. Briefly, the appearance of granules and the extensive surface-connected open canalicular membrane system as well as a substantial decrease in the nucleus:cytoplasm volume distribution, indicates that the megakaryocyte population  
5 has completed the process of polyploidization but has not yet generated a major portion of their final complement of platelet-specific cytoplasmic components.

In another embodiment, subjects are irradiated as above and active agent is injected subcutaneously before, at the time of, and after irradiation. Blood samples are taken at various times after administration of the active agent to monitor the  
10 number of white blood cells, megakaryocytes and platelets. In a preferred embodiment, subjects are treated with total body irradiation and active agent is administered subcutaneously (10 µg/kg/day or 100 µg/kg/day) at various times before and after irradiation. The number of white blood cells, megakaryocytes and platelets is preferably determined by counting with a hemacytometer followed by differential  
15 morphologic analysis.

In another embodiment of this aspect of the invention, hematopoietic precursor cells are isolated from bone marrow, peripheral blood or umbilical cord blood and cultured under appropriate growth conditions, in the presence of the active agents. Megakaryocyte production is assessed at various time points during culture  
20 by differential morphologic analysis.

In a preferred embodiment, hematopoietic precursor cells are isolated from bone marrow aspirates from the posterior iliac crest (Caplan and Haynesworth, U.S. Patent No. 5,486,359). CD34<sup>+</sup> hematopoietic precursor cells are isolated from the aspirate by attaching a biotinylated monoclonal antibody specific for CD34 (available

from Becton Dickinson, Sunnyvale, CA, USA) to a streptavidin affinity column (Ceprate SC; CellPro, Bothell, WA, USA) and passing the aspirate through the column, followed by appropriate column washing and stripping, according to standard techniques in the art. The isolated cells are suspended in culture medium and  
5 incubated in the presence of, preferably, between about 0.1 ng/ml and about 10 mg/ml of the active agents of the invention. The cells are expanded for a period of between 8 and 21 days and megakaryocyte production is assessed via phase microscopy to detect increased size and polyploidization at various points during this time period.

In a further embodiment of the present invention, a method of increasing  
10 megakaryocyte production and mobilization and platelet production by exposure to the active agents is disclosed, either in the presence or absence of other growth factors and cytokines. Examples of such growth factors and cytokines include, but are not limited to thrombopoietin, lymphokines, interleukins - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, granulocyte colony-stimulating factor, granulocyte/macrophage colony stimulating  
15 factor, macrophage colony-stimulating factor, tumor necrosis factor, epidermal growth factor, fibroblast growth factor, platelet derived growth factor, transforming growth factor beta, and stem cell factor.

In a further preferred embodiment, megakaryocytes and/or platelets that have been cultured in the presence of the active agents are used for autologous  
20 transplantation, to reconstitute a depleted hematopoietic system. Prior to transplantation, the cells are rinsed to remove all traces of culture fluid, resuspended in an appropriate medium and then pelleted and rinsed several times. After the final rinse, the cells are resuspended at between  $0.7 \times 10^6$  and  $50 \times 10^6$  cells per ml in an appropriate medium and reinfused into a subject through intravenous infusions.

Following transplantation, subject peripheral blood samples are evaluated for increased megakaryocyte ploidy and platelet number by standard flow cytometry and cell sorting techniques. (Talmadge, et al., *supra*).

In another aspect of the present invention the active agents are used to increase  
5 *in vivo* megakaryocyte production and mobilization and platelet production. For use  
in increasing megakaryocyte production and mobilization and platelet production, the  
active agents may be administered by any suitable route, including orally, parentally,  
by inhalation spray, rectally, or topically in dosage unit formulations containing  
conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term  
10 parenteral as used herein includes, subcutaneous, intravenous, intramuscular,  
intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques  
or intraperitoneally.

The active agents of all aspects of the present invention may be administered  
by any suitable route, including orally, parentally, by inhalation spray, rectally, or  
15 topically in dosage unit formulations containing conventional pharmaceutically  
acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein  
includes, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal,  
intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or  
intraperitoneally.

20 The active agents of the invention may be made up in a solid form (including  
granules, powders or suppositories) or in a liquid form (*e.g.*, solutions, suspensions, or  
emulsions). The compounds of the invention may be applied in a variety of solutions.  
Suitable solutions for use in accordance with the invention are sterile, dissolve  
sufficient amounts of the peptide, and are not harmful for the proposed application. In

this regard, the compounds of the present invention are very stable but are hydrolyzed by strong acids and bases. The compounds of the present invention are soluble in organic solvents and in aqueous solutions at pH 5-8.

The active agents may be subjected to conventional pharmaceutical operations  
5 such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. For administration, the active agents are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc,  
10 magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions,  
15 ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

20 Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (*e.g.*, liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

The dosage regimen for mitigating radiation-induced tissue damage and improving the efficacy of radiation therapy with the active agents is based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods. Dosage levels of the order of between 0.1 ng/kg and 10 mg/kg body weight of the active agents are useful for all methods of use disclosed herein.

The treatment regime will also vary depending on the disease being treated, based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. For example, the active agents are administered to an oncology patient for up to 30 days prior to a course of radiation therapy and for up to 60 days post-radiation exposure. The therapy is administered for 1 to 6 times per day at dosages as described above.

In all of these embodiments, the compounds of the invention can be administered either prior to, simultaneously with, or subsequent to radiation exposure.

In a preferred embodiment, the active agent is administered subcutaneously. A suitable subcutaneous dose of active ingredient of active agent is preferably between about 0.1 ng/kg and about 10 mg/kg administered twice daily for a time sufficient to mitigate radiation-induced tissue damage, to provide a radioprotective effect for a radiation therapy patient afflicted with a neoplastic disease, to effectively treat a patient in need of radiation therapy, to support bone marrow transplantation and to promote megakaryocyte production and mobilization and platelet production.

In a more preferred embodiment, the concentration of active agent is between about 100 ng/kg body weight and about 10.0 mg/kg body weight. In a most preferred embodiment, the concentration of active agent is between about 10 µg/kg body weight and about 10.0 mg/kg body weight. This dosage regimen maximizes the therapeutic  
5 benefits of the subject invention while minimizing the amount of agonist or peptide needed. Such an application minimizes costs as well as possible deleterious side effects.

For subcutaneous administration, the active ingredient may comprise from 0.0001% to 10% w/w, *e.g.*, from 1% to 2% by weight of the formulation, although it  
10 may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

In another preferred embodiment of the present invention, the active agent is administered topically. Suitable topical doses and active ingredient concentration in the formulation are as described for subcutaneous administration.

15 In a preferred embodiment of all of the aspects of the invention, the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,  
20 SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; and SEQ ID NO:37.

In a further preferred embodiment of the above aspects of the invention, administration of the active agent is localized to the area affected by the tissue-damaging radiation.

In another aspect of the present invention, an improved cell culture medium is provided for megakaryocyte and platelet production, wherein the improvement comprises addition to the cell culture medium of an effective amount of between about 0.1 ng and 10 mg/ml of the active agents of the invention. Any cell culture media that can support megakaryocyte and platelet production can be used with the present invention. Such cell culture media include, but are not limited to Basal Media Eagle, Dulbecco's Modified Eagle Medium, Iscove's Modified Dulbecco's Medium, McCoy's Medium, Minimum Essential Medium, F-10 Nutrient Mixtures, Opti-MEM® Reduced-Serum Medium, RPMI Medium, and Macrophage-SFM Medium or combinations thereof.

The improved cell culture medium can be supplied in either a concentrated (ie: 10X) or non-concentrated form, and may be supplied as either a liquid, a powder, or a lyophilizate. The cell culture may be either chemically defined, or may contain a serum supplement. Culture media is commercially available from many sources, such as GIBCO BRL (Gaithersburg, MD) and Sigma (St. Louis, MO)

In a further aspect, the present invention provides kits for megakaryocyte and platelet production, wherein the kits comprise an amount effective for megakaryocyte and platelet production of the active agents of the invention, and instructions for its use as a cell culture media supplement.

In a preferred embodiment, the kits further comprise cell culture growth medium. Any cell culture media that can support megakaryocyte and platelet



production can be used with the present invention. Examples of such cell culture media are described above. The cell culture medium can be supplied in either a concentrated (ie: 10X) or non-concentrated form, and may be supplied as either a liquid, a powder, or a lyophilizate. The cell culture may be either chemically defined,  
5 or may contain a serum supplement.

In a further preferred embodiment, the kit further comprises a sterile container, which can comprise either a sealed container, such as a cell culture flask, a roller bottle, or a centrifuge tube, or a non-sealed container, such as a cell culture plate or microtiter plate (Nunc; Naperville, IL).

10 In another preferred embodiment, the kit further comprises an antibiotic supplement for inclusion in the reconstituted cell growth medium. Examples of appropriate antibiotic supplements include, but are not limited to actinomycin D, Fungizone®, kanamycin, neomycin, nystatin, penicillin, streptomycin, or combinations thereof (GIBCO).

15 The present invention may be better understood with reference to the accompanying example that is intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

20 *Example 1 Effect of AII on rat mortality and white blood cell recovery after irradiation*

Female C57B1/6 mice (Jackson Labs, Bar Harbor, Maine) were irradiated with 600 cGy total body irradiation. Subcutaneous injection with either AII (10 µg/kg/day or 100 µg/kg/day) or saline (placebo) was initiated two days before (-day

2), on the day of (day 0) or 2 days after (+ day 2) irradiation and continued until the animals succumbed to the irradiation or were necropsied. At various times after irradiation, the mice were anaesthetized with Metofane (Pittman-Moore Animal Health, NZ) and bled via the retro-orbital sinus. Red blood cells were lysed with 0.3% acetic acid and the number of white blood cells was determined by counting with a hemacytometer. The data in Figures 1-3 show that administration of AII starting at two days prior to irradiation did not protect against mortality resulting from irradiation (Figure 1), but that AII administration on the day of irradiation (Figure 2) or two days after irradiation (Figure 3) substantially increased survival. Furthermore, AII administration at all time periods tested increased the number of circulating white blood cells (Figures 4-6). Further experiments demonstrated that AII administration increased the number of megakaryocytes (Figures 7-9), monocytes (Figures 10-12), neutrophils (Figures 13-15), and lymphocytes (Figures 16-18). These data demonstrate that *in vivo* administration of AII can improve hematopoietic recovery after irradiation.

*Example 2. Effect of AII and AII Analogs/Fragments on WBC and platelet numbers After Irradiation*

The animals were irradiated and treated as in Example 1, however, treatment started on day 0 only with one subcutaneous injection of either 10 µg/kg or 100 µg/kg daily until the study was terminated. Analogues and fragments of AII (see Table 3) were assessed for their effect on WBC recovery and platelet number after irradiation. The data are shown in Figures 20 and 21 and show that the peptides increase the production of both of these blood elements.

**Table 3: Designation for Analogues/Fragments**

Name	Abbreviation	Sequence	SEQ ID NO:
5 GSD 28	Ile <sup>8</sup> -AII	DRVYIHPI	SEQ ID NO: 38
GSD 24B	Pro <sup>3</sup> -AII	DRPYIHPF	SEQ ID NO:31
GSD 22A	Ala <sup>4</sup> -AIII	RVYAHPF	SEQ ID NO:18
AII(1-7)		DRVYIHP	SEQ ID NO:4
10 AII		DRVYIHPF	SEQ ID NO. 1

*Example 3. Effect of AII on survival of mice receiving bone marrow transplantation after lethal irradiation*

15 Donor C57B1/6 mice (female, 6-8 weeks old) were irradiated with 600 cGy total body irradiation. Starting on the day of irradiation, the mice received either saline (0.1 ml) or 20 µg/ml angiotensin II (0.1 ml, 100 µg/kg) subcutaneously for fourteen days. At the end of this period, the bone marrow was harvested from the

20 femur by flushing and the number of viable nucleated cells determined by counting under a light microscope on a hemacytometer in the presence of trypan blue.

These donor bone marrow cells were then injected intravenously into recipient mice (female C57B1/6, 6-8 weeks old) that had been lethally irradiated (900 cGy total body irradiation) at two concentrations:  $1 \times 10^6$  or  $1 \times 10^5$  cells per mouse. After

25 injection, the recipient mice received either saline or 100 µg/kg AII subcutaneously until death or termination. The study design in its entirety is as follows:

<u>Donor</u>	<u>Recipient</u>	<u>Cell Number</u>
Saline	Saline	$1 \times 10^6$
Saline	Saline	$1 \times 10^5$
30 Saline	AII	$1 \times 10^6$
Saline	AII	$1 \times 10^5$
AII	Saline	$1 \times 10^6$
AII	Saline	$1 \times 10^5$
AII	AII	$1 \times 10^6$
35 AII	AII	$1 \times 10^5$

The survival of the mice and the number of circulating white blood cells were measured as a function of time post-bone marrow transplantation. The data are presented in Figures 22-24, and demonstrate that AII treatment increased both survival and white blood cell number in mice receiving bone marrow transplantation after irradiation. The greatest benefit was conferred by treatment of both the donor bone marrow cells and the recipient mice with AII.


The methods and kits of the present invention, by mitigating radiation induced tissue damage and improving the efficacy of radiation therapy, significantly enhance the utility of presently available treatments both for radiation-induced tissue damage and for clinical radiation therapy, as well as bone marrow transplantation by increasing the survival rate of patients and accelerating the reconstitution of the patient's hematopoietic system. Similarly, by providing a method for megakaryocyte and platelet production, the present invention will greatly augment clinical cancer treatments and bone marrow transplantation and other conditions that lead to decreased megakaryocyte production and mobilization and platelet production.

The method of the present invention also increases the potential utility of megakaryocytes as vehicles for gene therapy in hematopoietic disorders, by providing a more efficient means to rapidly expand transfected megakaryocytes.

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the full scope of the appended claims.

We claim:

1. A method for the mitigation of tissue damage due to radiation exposure comprising the administration of an amount effective for the mitigation of tissue damage of at least one active agent comprising a sequence consisting of at least three  
5 contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

10  $R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

20  $R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;


$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group.

2. The method of claim 1 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; and SEQ ID NO: 38.

3. An improved method of radiation therapy for a patient afflicted with a neoplastic disease state, the improvement comprising administering in conjunctive therapy an effective radioprotective amount of at least one active agent comprising a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I

15



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

20

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

5  $R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group.

4. The method of claim 3 wherein the active agent is selected from the group  
10 consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,  
15 SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; and SEQ ID NO: 38.

5. An improved method of treating a patient in need of radiation therapy, whereby the improvement comprises administering to said patient an amount effective  
20 for treating a patient in need of radiation therapy of at least one active agent comprising a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

5  $R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

10  $R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

15  $R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group.

6. The method of claim 5 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32,



SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37;  
and SEQ ID NO: 38.

7. The method of claim 1, 3, or 5 wherein the active agent is SEQ ID NO:1, SEQ  
ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID  
5 NO:34, and SEQ ID NO:38.

8. A kit for treating a patient afflicted with a neoplastic disease state, comprising:  
(a) an effective radioprotective amount of at least one active agent  
comprising a sequence consisting of at least three contiguous amino acids of groups  
 $R^1$ - $R^8$  in the sequence of general formula I

10  $R^1$ - $R^2$ - $R^3$ - $R^4$ - $R^5$ - $R^6$ - $R^7$ - $R^8$

in which  $R^1$  and  $R^2$  together form a group of formula

$X$ - $R^A$ - $R^B$ -,

wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet,  
15 Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-  
Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile,  
Gly, Pro, Aib, Acpc, Lys, and Tyr;

20  $R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser,  
homoSer, Ala, and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val  
and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group, and

- (b) instructions for using the effective radioprotective amount of active agent for treating a patient with a neoplastic disease.

9. The kit of claim 8 wherein the active agent is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; and SEQ ID NO: 38.


10. The kit of claim 8, further comprising a means for delivery of the active agent.

11. A kit for treating a patient in need of radiation therapy, comprising:

- (a) an amount effective to treat a patient in need of radiation therapy of at least one active agent comprising a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

R<sup>A</sup> is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

R<sup>B</sup> is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

5 R<sup>3</sup> is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

R<sup>4</sup> is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

10 R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R<sup>6</sup> is His, Arg or 6-NH<sub>2</sub>-Phe;

R<sup>7</sup> is Pro or Ala; and

R<sup>8</sup> is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R<sup>4</sup> as a terminal Tyr group, and

15 (b) instructions for using the amount effective of active agent to treat a patient in need of radiation therapy.

12. The kit of claim 11 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32,


20

SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37;  
and SEQ ID NO: 38.


13. The kit of claim 11, further comprising a means for delivery of the active agent.

5 14. The kit of claim 8 or 11 wherein the active agent is SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

15. An improved method of bone marrow transplantation, the improvement comprising administering an effective amount of at least one active agent comprising  
10 a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



15 wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

20  $R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and


5  $R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group.

16. The method of claim 15 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, 10 SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; 15 and SEQ ID NO: 38.

17 The method of claim 15 wherein the active agent is SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

18.. A bone marrow transplantation kit, comprising:

20 (a) an amount effective to support bone marrow transplantation of at least one active agent comprising a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

5  $R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

10  $R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

15  $R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including  $R^4$  as a terminal Tyr group, and

(b) instructions for using the effective amount of active agent for supporting bone marrow transplantation.

19. The kit of claim 18 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,

SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32,  
 SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37;  
 and SEQ ID NO: 38.

20. The kit of claim 18 wherein the active agents is SEQ ID NO:1, SEQ ID NO:4,  
 5 SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34,  
 and SEQ ID NO:38.

21. The kit of claim 18 further comprising a means for delivery of the active  
 agent.

22. A method for increasing megakaryocyte production and mobilization and  
 10 platelet production in a mammal, which comprises administering to the mammal an  
 amount effective for megakaryocyte production and mobilization and platelet  
 production of at least one active agent comprising a sequence consisting of at least  
 three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



15 in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet,  
 Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

20  $R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-  
 Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile,  
 Gly, Pro, Aib, Acpc, Lys, and Tyr;

R<sup>4</sup> is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

5 R<sup>6</sup> is His, Arg or 6-NH<sub>2</sub>-Phe;

R<sup>7</sup> is Pro or Ala; and

R<sup>8</sup> is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R<sup>4</sup> as a terminal Tyr group.

23. The method of claim 22, wherein the active agent is selected from the group  
10 consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27,  
15 SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; and SEQ ID NO: 38.

24. The method of claim 22 wherein the active agent is SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID  
20 NO:34, and SEQ ID NO:38.

25. An improved cell culture medium for megakaryocyte and platelet production, wherein the improvement comprises addition to the cell culture medium of an amount effective to accelerate megakaryocyte and platelet production of at least one active



agent comprising a sequence consisting of at least three contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet, Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser, homoSer, Ala, and azaTyr;

$R^5$  is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

$R^6$  is His, Arg or 6-NH<sub>2</sub>-Phe;

$R^7$  is Pro or Ala; and

$R^8$  is selected from the group consisting of Phe, Phe(Br), Ile and Tyr,

excluding sequences including  $R^4$  as a terminal Tyr group.

26. The improved cell culture medium of claim 20 wherein the active agent is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID

NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID  
 NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID  
 NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID  
 NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID  
 5 NO:36; SEQ ID NO:37; and SEQ ID NO: 38.

27. The improved cell culture medium of claim 20 wherein the active agent is  
 SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ  
 ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

28. A kit for megakaryocyte and platelet production, comprising:

10 (a) an amount effective to increase megakaryocyte and platelet production,  
 of at least one active agent comprising a sequence consisting of at least three  
 contiguous amino acids of groups  $R^1$ - $R^8$  in the sequence of general formula I



in which  $R^1$  and  $R^2$  together form a group of formula



wherein X is H or a one to three peptide group

$R^A$  is selected from Asp, Glu, Asn, Acpc, Ala, Me<sup>2</sup>Gly, Pro, Bet,  
 Glu(NH<sub>2</sub>), Gly, Asp(NH<sub>2</sub>) and Suc;

$R^B$  is selected from Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-  
 20 Lys;

$R^3$  is selected from the group consisting of Val, Ala, Leu, norLeu, Ile,  
 Gly, Pro, Aib, Acpc, Lys, and Tyr;

$R^4$  is selected from the group consisting of Tyr, Tyr(PO<sub>3</sub>)<sub>2</sub>, Thr, Ser,  
 homoSer, Ala, and azaTyr;

R<sup>5</sup> is selected from the group consisting of Ile, Ala, Leu, norLeu, Val and Gly;

R<sup>6</sup> is His, Arg or 6-NH<sub>2</sub>-Phe;

R<sup>7</sup> is Pro or Ala; and

5 R<sup>8</sup> is selected from the group consisting of Phe, Phe(Br), Ile and Tyr, excluding sequences including R<sup>4</sup> as a terminal Tyr group; and

(b) instructions for using the amount effective of active agent as a cell culture medium supplement.

29. The kit of claim 28, further comprising cell growth medium.

10 30. The kit of claim 28 further comprising a sterile container.

31. The kit of claim 28 wherein the active agent is selected from the group consisting of SEQ ID NO. 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34; SEQ ID NO:35, SEQ ID NO:36; SEQ ID NO:37; and SEQ ID NO: 38.

20 32. The kit of claim 28 wherein the active agent is SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

33. A method for the mitigation of tissue damage due to radiation exposure comprising the administration of an amount effective for the mitigation of tissue

damage of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

5 R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent.

34. The method of claim 33 wherein the active agent is selected from the group  
10 consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID  
NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

35. An improved method of radiation therapy for a patient afflicted with a  
neoplastic disease state, the improvement comprising administering in conjunctive  
therapy an effective radioprotective amount of at least one active agent comprising a  
15 sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

20 R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent.

36. The method of claim 35 wherein the active agent is selected from the group  
consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID  
NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

37. An improved method of treating a patient in need of radiation therapy, whereby the improvement comprises administering to said patient an amount effective for treating a patient in need of radiation therapy of at least one active agent comprising a sequence of the following general formula:

5

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

10

R5 is Phe, Ile, or is absent.

38. The method of claim 37 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

39. A kit for treating a patient afflicted with a neoplastic disease state, comprising:

15

(a) an effective radioprotective amount of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

20

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent, and

(b) instructions for using the effective radioprotective amount of active agent for treating a patient with a neoplastic disease.

40. The kit of claim 39 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

41. The kit of claim 39, further comprising a means for delivery of the active agent.

42. A kit for treating a patient in need of radiation therapy, comprising:

(a) an amount effective to treat a patient in need of radiation therapy of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent, and

(b) instructions for using the amount effective of active agent to treat a patient in need of radiation therapy.

43. The kit of claim 42 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

44. The kit of claim 42, further comprising a means for delivery of the active agent.

45. An improved method of bone marrow transplantation, the improvement comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

5 R5 is Phe, Ile, or is absent.

46. The method of claim 45 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

47. A bone marrow transplantation kit, comprising:

10 (a) an amount effective to support bone marrow transplantation of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

15 R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent, and

(b) instructions for using the effective amount of active agent for supporting bone marrow transplantation.

20 48. The kit of claim 47 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

49. The kit of claim 47 further comprising a means for delivery of the active agent.

50. A method for increasing megakaryocyte production and mobilization and platelet production in a mammal, which comprises administering to the mammal an amount effective for megakaryocyte production and mobilization and platelet production of at least one active agent comprising a sequence of the following general

5 formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

10 R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent.

51. The method of claim 50, wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

15 52. An improved cell culture medium for megakaryocyte and platelet production, wherein the improvement comprises addition to the cell culture medium of an amount effective to accelerate megakaryocyte and platelet production of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

20 wherein R1 is selected from the group consisting of H and Asp;

R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent.



53. The improved cell culture medium of claim 52 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

5 54. A kit for megakaryocyte and platelet production, comprising:

(a) an amount effective to increase megakaryocyte and platelet production, of at least one active agent comprising a sequence of the following general formula:

R1-Arg-R2-R3-R4-His-Pro-R5

wherein R1 is selected from the group consisting of H and Asp;

10 R2 is selected from the group consisting of Val and Pro;

R3 is selected from the group consisting of Tyr and Tyr(PO<sub>3</sub>)<sub>2</sub>;

R4 is selected from the group consisting of Ala, Ile, Leu, and norLeu; and

R5 is Phe, Ile, or is absent; and

15 (b) instructions for using the amount effective of active agent as a cell culture medium supplement.


55. The kit of claim 54, further comprising cell growth medium.

56. The kit of claim 54 further comprising a sterile container.

57. The kit of claim 54 wherein the active agent is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:26, SEQ ID  
20 NO:31, SEQ ID NO:32, SEQ ID NO:34, and SEQ ID NO:38.

# Effect of All on Mortality Post-Irradiation

Post 600 cGy



Treatment Initiated Day -2

F<sub>5</sub>1

# Effect of All on Mortality Post-Irradiation

Post 600 cGy





Fig 2

Treatment Initiated Day 0

# Effect of All on Mortality Post-Irradiation


Post 600 cGy



F<sub>15</sub> 3

Treatment Initiated Day +2

# Effect of All on WBC Number After Irradiation




F<sub>5</sub> 4

600 cGv. -d2

# Effect of All on WBC Number

After Irradiation



600 cGv. d0

# Effect of All on WBC Number

## After Irradiation





Fig 6

600 cGv. +d2


# Effect of All on Megakaryocyte Number After Irradiation



600 cGy, -d2



# Effect of All on Megakaryocyte Number After Irradiation



600 cGy, d0

# Effect of All on Megakaryocyte Percent After Irradiation





Fig 9

600 cGv. +d2

# Effect of All on Monocyte


Number After Irradiation



Fy10

600 cGy, -d2

# Effect of All on Monocyte Number After Irradiation



600 cGy, d0


# Effect of AI on Monocyte

Number After Irradiation

WO 99/45945

12/24

PCT/US99/05194



600 cGy, +d2

# Effect of All on Neutrophil

Number After Irradiation




Fig 13

600 cGy, -d2

# Effect of All on Neutrophil

Number After Irradiation





Fig. 14

600 cGy, d0

# Effect of All on Neutrophil


Number After Irradiation



600 cGy, +d2




# Effect of All on Lymphocyte Number After Irradiation



600 cGy, -d2

# Effect of All on Lymphocyte Number After Irradiation



600 cGy, d0

# Effect of All on Lymphocyte

Number After Irradiation




Fig 18

600 cGy, +d2

# Effect of All Analogues on Recovery from Irradiation

WO 99/45945

19 / 24

PCT/US99/05194




Fig 19

600 cGy

# Effect of All Analogues on Recovery from Irradiation




Fig 20

600 cGy

# Effect of Angiotensin II on Survival

After Bone Marrow Transplantation

WO 99/45945

21 / 24

PCT/US99/05194




FIG. 21

Irradiated Donor, 1 million cells/mouse


# Effect of Angiotensin II on Survival

## After Bone Marrow Transplantation

WO 99/45945

22 / 24

PCT/US99/05194



F16 22

Irradiated Donor, 100,000 cells/mouse

# Effect of Angiotensin II on White Blood Cell Number in the Blood after Bone Marrow Transplantation

WO 99/45945

23 / 24

PCT/US99/05194




Fig. 16 - 23

Donor:Recipient Source

Irradiated Donor, 1 million cells/mouse




# Effect of Angiotensin II on White Blood Cell Number in the Blood after Bone Marrow Transplantation

WO 99/45945

24 / 24

PCT/US99/05194



F16 916 24

Donor:Recipient Source

Irradiated Donor, 100,000 cells/mouse

SEQUENCE LISTING

<110> Kathleen Rodgers and Gere diZerega

<120> Improved Radiation Therapy Methods

<130> 97,017-K2

<140> To be assigned

<141> To be assigned

<160> 38

<170> PatentIn Ver. 2.0

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:angiotensin II

<400> 1

Asp Arg Val Tyr Ile His Pro Phe

1

5

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII2-8

<400> 2

Arg Val Tyr Ile His Pro Phe

1

5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(3-8)

<400> 3

Val Tyr Ile His Pro Phe

1

5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(1-7)

<400> 4

Asp Arg Val Tyr Ile His Pro

1

5

<210> 5

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII (2-7)

<400> 5

Arg Val Tyr Ile His Pro

1

5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII (3-7)

<400> 6

Val Tyr Ile His Pro

1

5

<210> 7

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(5-8)

<400> 7

Ile His Pro Phe

1

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(1-6)

<400> 8

Asp Arg Val Tyr Ile His

1

5

<210> 9

<211> 5

<212> PRT



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(1-5)

<400> 9

Asp Arg Val Tyr Ile

1

5

<210> 10

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(1-4)

<400> 10

Asp Arg Val Tyr

1

<210> 11

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(1-3)

<400> 11

Asp Arg Val

1

<210> 12

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> Xaa at postion 2 is Nle

<222> 2

<223> Description of Artificial Sequence: AII analogue

<400> 12

Arg Xaa Tyr Ile His Pro Phe

1

5

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> Xaa at position 4 is Nle

<222> 4

<223> Description of Artificial Sequence: AII analogue

<400> 13

Arg Val Tyr Xaa His Pro Phe

1

5

<210> 14

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(6-8)

<400> 14

His Pro Phe

1

<210> 15

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII(4-8)

<400> 15

Tyr Ile His Pro Phe

1

5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> Xaa at position 1 can be Hydrogen, Arg, Lys, Ala, Or  
n,  
Ser(Acetylated), MeGly, D-Arg, or D-Lys; Xaa at position

2  
can be Val, Ala, Leu, Nle, Ile, Gly, Pro, Aib, Acp, or Ty  
r;  
Xaa at position 4 can be Ile, Ala, Leu, Nle, Val, or Gly

<222> 1-4

<223> Description of Artificial Sequence: AII analogue

class

<400> 16

Xaa Xaa Tyr Xaa His Pro Phe

1.

5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue

<400> 17

Arg Val Tyr Gly His Pro Phe

1

5

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue

<400> 18



Arg Val Tyr Ala His Pro Phe

1

5

<210> 19

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue i

<400> 19

Asp Arg Val Tyr Val His Pro Phe

1

5

<210> 20

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 2

<400> 20

Asn Arg Val Tyr Val His Pro Phe

1

5

<210> 21

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 3

<400> 21

Ala Pro Gly Asp Arg Ile Tyr Val His Pro Phe

1

5

10

<210> 22

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 4

<400> 22

Glu Arg Val Tyr Ile His Pro Phe

1

5

<210> 23

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 5

<400> 23

Asp Lys Val Tyr Ile His Pro Phe

1

5

<210> 24

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 6

<400> 24

Asp Arg Ala Tyr Ile His Pro Phe

1

5

<210> 25

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analoge 7

<400> 25

Asp Arg Val Thr Ile His Pro Phe

1

5

<210> 26

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 8

<400> 26

Asp Arg Val Tyr Leu His Pro Phe

1

5

<210> 27

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 9

<400> 27

Asp Arg Val Tyr Ile Arg Pro Phe

1

5

<210> 28

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 10

<400> 28

Asp Arg Val Tyr Ile His Ala Phe



1

5

<210> 29

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 11

<400> 29

Asp Arg Val Tyr Ile His Pro Tyr

1

5

<210> 30

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 12

<400> 30

Pro Arg Val Tyr Ile His Pro Phe

1

5

<210> 31

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII Analogue 13

<400> 31

Asp Arg Pro Tyr Ile His Pro Phe

1

5

<210> 32

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<221> PHOSPHORYLATION

<222> 4

<223> Description of Artificial Sequence: AII Analogue 14

<400> 32

Asp Arg Val Tyr Ile His Pro Phe

1

5

<210> 33

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<221> Xaa at position 3 is Nle

<222> 3

<223> Description of Artificial Sequence: AII Analogue 15

<400> 33

Asp Arg Xaa Tyr Ile His Pro Phe

1

5

<210> 34

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<221> Xaa at position 5 is Nle

<222> 5

<223> Description of Artificial Sequence: AII Analogue 16

<400> 34

Asp Arg Val Tyr Xaa His Pro Phe

1

5

<210> 35

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<221> homo Ser

<222> 4

<223> Description of Artificial Sequence: AII Analogue 17

<400> 35

Asp Arg Val Ser Tyr Ile His Pro Phe

1

5

<210> 36

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:p-aminophenylalanine 6 AII

<400> 36

Asp Arg Val Tyr Ile Xaa Pro Phe

1

5

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:angiotensin I

<400> 37

Asp Arg Val Tyr Ile His Pro Phe His Leu

1

5

10

<210> 38

<211> 8

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial

Sequence:1GD: Ile8-AII

<400> 38

Asp Arg Val Tyr Ile His Pro Ile

1

5

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/05194

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K38/08 C07K7/14 C12N5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 265 400 A (FERRING AB) 27 April 1988	1-14, 33-44
Y	see page 2	15-32, 45-57
Y	<p>--- J.E. MOULDER ET AL.: "Angiotensin II receptor antagonists in the prevention of radiation nephropathy" RADIATION RESEARCH, vol. 146, no. 1, July 1996, pages 106-110, XP002107771 cited in the application see page 106 see abstract --- -/-</p>	15-32, 45-57

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

30 June 1999

Date of mailing of the international search report

12/07/1999

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

# INTERNATIONAL SEARCH REPORT

Inter. Patent Application No  
PCT/US 99/05194

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	T. KATO ET AL.: "New modality of radiation therapy under increased tumor oxygen tension with angiotensin II: A pilot study" RADIATION MEDICINE, vol. 11, no. 3, 1993, pages 86-90, XP002107772 see page 86, column 2 ---	
A	WO 97 34627 A (INST NAT SANTE RECH MED ;WDZIECZAK BAKALA JOANNA (FR); LENFANT MAR) 25 September 1997 ---	
A	US 5 716 935 A (DIZEREGA GERE STODDER ET AL) 10 February 1998 cited in the application ---	
A	US 5 015 629 A (DIZEREGA GERE S) 14 May 1991 cited in the application -----	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 05194

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-7, 15-17, 22-24, 33-38, 45-46, 50-51 are directed at least in part to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
claims: 1, 3, 5, 8, 11, 15, 18, 22, 25, 28  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/05194

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0265400	A	27-04-1988	SE 457055 B AT 64308 T AU 609417 B AU 7852887 A DK 206688 A FI 890715 A JP 2500668 T SE 8603481 A WO 8801163 A	28-11-1988 15-06-1991 02-05-1991 08-03-1988 13-06-1988 15-02-1989 08-03-1990 19-02-1988 25-02-1988
WO 9734627	A	25-09-1997	NONE	
US 5716935	A	10-02-1998	AU 697504 B AU 7836494 A CA 2172494 A EP 0745091 A JP 9503205 T WO 9508565 A ZA 9407337 A	08-10-1998 10-04-1995 30-03-1995 04-12-1996 31-03-1997 30-03-1995 10-05-1995
US 5015629	A	14-05-1991	NONE	